Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches.

Area of Science:

• Endocrinology
• Pharmacology
• Oncology

Background:

• Acromegaly is primarily treated with pituitary surgery.
• Medical therapies are used for persistent disease or as primary treatment in select cases.
• Current medical options include somatostatin receptor ligands, dopamine agonists, and growth hormone receptor antagonists.

Purpose of the Study:

• To review current and emerging medical therapies for acromegaly.
• To highlight the role of medical therapy in managing acromegaly.
• To discuss unmet needs and future directions in acromegaly treatment.

Main Methods:

• Literature review of current and investigational acromegaly treatments.
• Analysis of existing drug classes and their limitations.
• Exploration of novel therapeutic agents in development.

Main Results:

• Existing therapies (SRLs, dopamine agonists, GH receptor antagonists) are often effective but can have limitations.
• Investigational drugs include new SRL formulations, novel SRLs, monoclonal antibodies, and new GH receptor antagonists.
• These emerging therapies aim to address unmet needs such as intolerance and lack of sustained efficacy.

Conclusions:

• Current and emerging therapies provide renewed hope for acromegaly management.
• Further research with comparator agents, biomarkers, and predictive models is needed.
• Optimizing patient care requires addressing individual needs and improving therapeutic effectiveness.